RI
RTW Investments Portfolio holdings
AUM
$9.98B
1-Year Est. Return
115.73%
This Fund
S&P 500
1 Year Est. Return
+115.73%
AUM
$9.98B
AUM Growth
+$1.87B
(+23%)
Holding
103
Top Buys
| 1 | +$321M | |
| 2 | +$209M | |
| 3 | +$180M | |
| 4 |
Repligen
RGEN
|
+$167M |
| 5 |
Cogent Biosciences
COGT
|
+$116M |
Top Sells
| 1 | +$496M | |
| 2 | +$260M | |
| 3 | +$191M | |
| 4 |
Natera
NTRA
|
+$104M |
| 5 |
Stryker
SYK
|
+$89.3M |
Sector Composition
| 1 | Healthcare | 99.9% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$12B
| $1.16B | 11.63% |
1,993,687
|
|
||
2
Insmed
INSM
$31B
| $843M | 8.44% |
4,842,879
+1,758,321
|
|
||
3
PTC Therapeutics
PTCT
$5.96B
| $588M | 5.89% |
7,746,415
|
|
||
4
argenx
ARGX
$52B
| $566M | 5.67% |
673,497
|
|
||
5
Protagonist Therapeutics
PTGX
$6.59B
| $442M | 4.43% |
5,059,053
-697,224
|
|
||
|
6
Natera
NTRA
$28.6B
| $344M | 3.44% |
1,500,000
-500,000
|
|
||
7
RadNet
RDNT
$4.9B
| $281M | 2.81% |
3,938,500
+1,122,956
|
|
||
8
Tarsus Pharmaceuticals
TARS
$2.88B
| $273M | 2.74% |
3,335,320
+157,884
|
|
||
|
9
Cogent Biosciences
COGT
$5.84B
| $270M | 2.7% |
7,592,241
+4,124,755
|
|
||
10
Penumbra
PEN
$13B
| $269M | 2.7% |
866,499
|
|
||
11
iRhythm Holdings
IRTC
$3.89B
| $210M | 2.1% |
+1,181,990
|
|
||
12
Apogee Therapeutics
APGE
$6.65B
| $205M | 2.05% |
2,712,097
|
|
||
13
Apellis Pharmaceuticals
APLS
$5.22B
| $193M | 1.93% |
+7,666,764
|
|
||
14
Acadia Pharmaceuticals
ACAD
$3.69B
| $191M | 1.91% |
7,144,524
|
|
||
15
Establishment Labs
ESTA
$1.88B
| $189M | 1.89% |
2,588,831
|
|
||
16
Stoke Therapeutics
STOK
$2.05B
| $176M | 1.76% |
5,546,856
+423,331
|
|
||
|
17
Repligen
RGEN
$7.23B
| $174M | 1.75% |
+1,064,000
|
|
||
18
Cytokinetics
CYTK
$7.94B
| $173M | 1.73% |
2,721,158
|
|
||
19
Immunocore
IMCR
$1.58B
| $169M | 1.69% |
4,869,798
|
|
||
20
Axsome Therapeutics
AXSM
$9.43B
| $162M | 1.62% |
888,001
-230,882
|
|
||
21
Guardant Health
GH
$11.2B
| $151M | 1.52% |
1,481,033
|
|
||
22
Neurocrine Biosciences
NBIX
$13B
| $151M | 1.51% |
1,062,072
|
|
||
23
Spyre Therapeutics
SYRE
$5.43B
| $137M | 1.37% |
4,171,996
+550,000
|
|
||
24
Zai Lab
ZLAB
$2.67B
| $123M | 1.23% |
6,959,032
+4,667,660
|
|
||
25
Immatics
IMTX
$1.43B
| $120M | 1.2% |
11,433,354
+2,617,737
|
|